Reported about 22 hours ago
Merck & Co., Inc. (NYSE: MRK) has announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA, a new treatment aimed at preventing respiratory syncytial virus in infants under 8 months. This approval comes after favorable results from clinical trials, demonstrating significant reductions in RSV-related medical issues. The final approval is pending from the CDC Director or the Health and Human Services Secretary.
Source: YAHOO